On July 21, the Central Drugs Standard Control Organisation granted marketing authorisation to Qdenga, the country’s first approved dengue vaccine. More than 24 million doses have been administered worldwide, and the vaccine has the WHO’s imprimatur. Clinical trials have shown that Qdenga provides long-lasting protection against all four dengue virus types in people who have had the disease. The WHO recommends that countries consider introducing Qdenga into routine immunisation only in areas where dengue transmission is a significant public health threat. Qdenga is a significant addition to India’s public health arsenal, but it should complement, not replace, a comprehensive strategy for controlling mosquito-borne diseases.